| Name | BAY-1895344 |
|---|---|
| Synonyms |
Elimusertib free base
Elimusertib, 10 mM in DMSO (R)-3-Methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-3-yl)-1,7-naphthyridin-2-yl)morpholine , Elimusertib 1,7-Naphthyridine, 2-[(3R)-3-methyl-4-morpholinyl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-3-yl) 3-methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-3-yl)-1,7-naphthyridin-2-yl)morpholine BAY-1895344 HCl(Elimusertib) BAY-1895344 diHCl BAY1895344;BAY 1895344;D MFCD31561442 D1213 BAY1895344;BAY 1895344;BAY-1895344 (R)-3-Methyl-4-[4-(1-methyl-5-pyrazolyl)-8-(5-pyrazolyl)-1,7-naphthyridin-2-yl]morpholine BAY 1895344 (BAY-1895344) (R)-3-methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-3-yl)-1,7-naphthyridin-2-yl)morpholine Elimusertib (R)-3-methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl)morpholine Elimusertib (BAY1895344) |
| Description | BAY-1895344 is a potent, orally available and selective ATR inhibitor, with IC50 of 7 nM. Anti-tumor activity[1]. |
|---|---|
| Related Catalog | |
| Target |
ATR:7 nM (IC50) |
| In Vitro | BAY-1895344 potently inhibits the proliferation of a broad spectrum of human tumor cell lines with a median IC50 of 78 nM[1]. BAY-1895344 potently suppresses hydroxyurea-induced H2AX phosphorylation (IC50, 36 nM)[1]. |
| In Vivo | BAY-1895344 shows potent anti-tumor efficacy in monotherapy in a variety of xenograft models of ovarian and colorectal cancer, and causes complete tumor remission in mantle cell lymphoma models[2]. |
| References |
| Molecular Formula | C20H22ClN7O |
|---|---|
| Molecular Weight | 411.89 |
| Storage condition | -20℃ |
| Hazard Codes | N |
|---|